Oxford Biomedica plc (OXB) Earnings Call Transcripts

Oxford Biomedica plc's Latest Earnings Call - March 26, 2026

In the preliminary results for the fiscal year 2025, Oxford Biomedica plc (OXB:GB) reported a significant revenue increase of 33% year-over-year, reaching GBP 170.9 million, which was at the upper end of management's guidance. The company achieved its first full year of operating EBITDA profitability, posting GBP 8.1 million compared to a loss of GBP 15.3 million in 2024. Management maintained its revenue guidance for 2026 at GBP 220 million to GBP 240 million, indicating strong visibility into future performance driven by a growing backlog and contracted orders.

Reported metrics

Guidance from management

Management reiterated revenue guidance for 2026 at GBP 220 million to GBP 240 million, with 60% already covered by contracted orders. They expect a strong second half of the year as the integration of the Durham facility progresses.

What management said

I'll take the FX and energy price question. So in terms of FX, I mean, we ended the year around [ 1 35 ], [ 1 34 ]. I think we're sort of bouncing around that level. And so at these rates, I'd expect the FX impact to be relatively minimal. In terms of energy rates, we locked in a lot of our rates fairly recently, most of our contracts come for renewal in 2027. So I think, again, some impacts, but all baked into expec...

Yes. I mean you've answered it perfectly. I think the level that you cited is the right level to think. Procurement services is expected to be a growing element of our revenue stream, but so are the higher-margin manufacturing and development services as well. So I would expect that mix to stay relatively the same, certainly in the near to medium term.

What analysts pressed on

Analysts expressed concerns regarding the deceleration in order growth in the second half of 2025, questioning whether this was due to lumpiness or other factors. There were also inquiries about the impact of the Durham facility on demand dynamics in the U.K. and the overall capacity management between the Durham and Bedford sites.

Main topics on the call

• Revenue Growth — Oxford Biomedica achieved a 33% increase in revenues for 2025, reaching GBP 170.9 million, reflecting strong demand for CDMO services. Management noted, "This growth reflects the successful execution of the company's pur...
• Operating EBITDA Profitability — The company reported an operating EBITDA profit of GBP 8.1 million, marking its first profitability since the strategic refocus. This is a significant turnaround from a loss of GBP 15.3 million in 2024, demonstrating imp...
• Backlog and Contracted Orders — The backlog increased by 36% to GBP 204 million, and contracted client orders rose by 20% to GBP 224 million. This growth provides strong visibility into revenue for 2026, as stated by management, "We have a lot of confi...
• Acquisition of Durham Facility — The acquisition of the Durham facility is expected to enhance OXB's U.S. manufacturing capabilities and support late-stage programs. Management highlighted that this facility "will strengthen our capacity to support late...

Read the full Oxford Biomedica plc transcript (March 26, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 18 Oxford Biomedica plc earnings call transcripts on record, spanning May 6, 2020 to June 2, 2026. Based on this history, Oxford Biomedica plc reports semi-annually. The most recent call on file is dated June 2, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

OXB

Exchange

LSE

Country

GB

Sector

Health Care

Industry

Biotechnology

Calls on record

18

First call

May 6, 2020

Most recent

June 2, 2026

Reporting cadence

semi-annually